Microbiome Therapeutics Market Foreseen to Grow Exponentially by 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. 

The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market.

Impact of COVID-19

There were numerous consequences due to the COVID-19 pandemic, especially because of the reduced access to care for other illnesses. As the number of individuals becoming ill from COVID-19 kept increasing and for the protection of healthy individuals from being affected by the disease, all non-urgent healthcare facilities were suspended as per respective government directives. Even though these measures were necessary, it had mostly negative impact on the Global microbiome therapeutics market. Some the major impacts were; interruption of key clinical trial activities, modification of clinical trial guidelines bringing in additional safety measures, and delay in regulatory agencies’ review and approval timeline.

Market Segmentation:

Within the research report, the market is segmented on the basis of:

•    target therapy area (gastrointestinal and infectious diseases, skin disorders, cancer indications, and other indications)
•    region (North America, Europe, Asia-Pacific, and Rest-of-the-World).

This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Segmentation 1: by Target Therapy Area

Disorders related to gastrointestinal (GI) and skin disorders command a major share of the microbiome therapeutics segment, and is expected to continue during the forecast period. Most of the microbiome therapeutics in advanced development stage are indicated to treat C.diff. infection (CDI) and expected to enter the market first. The indications selected were on the basis of research intensity in the specific therapy area. 

Segmentation 2: by Region

Asia-Pacific (APAC) is expected to dominate the global microbiome therapeutics market for the forecast period 2022-2032 continuuing with it overall contribution of approximately 40% of the total market size in 2021 followed by Europe with 32.59%. Increasing healthcare expenditure, coupled with government initiatives, are among the leading factors contributing to the growth of the market.

Demand – Drivers and Challenges

Some of the potential drivers identified by BIS Research includes:

•    Growing Strategic Activities in Microbiome Therapeutics Segment
•    Potential of Microbiome Therapeutics to Address Unmet Needs of Existing Treatment Options
•    Microbiome Therapeutic Products as a Safer Alternative to Conventional Drug Treatments

There are some challenges identified for the global microbiome therapeutics market are; Lack of standard regulatory guidelines and safety issues associated with live biotherapeutic products (LBPs).

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players leading the market include Sanofi S.A and Taisho Pharmaceutical Holding that capture around 88% of the market with Sanofi S.A holding 64.31% while Taisho Pharmaceutical Holdings 24.49% respectively. 

Some of the prominent established names in this market are:

•    4D pharma plc
•    Seres Therapeutics, Inc.
•    Microbiotica
•    Enterome
•    Enterome Biosciences
•    Destiny Pharma plc
•    Taisho Pharmaceutical Holdings
•    AOBiome Therapeutics, Inc.
•    Finch Therapeutics Group, Inc.
•    Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
•    MaaT Pharma
•    Vedanta Biosciences Inc.
•    OxThera AB
•    Pendulum Therapeutics
•    Caelus Health
•    Quorum Innovations
•    Sanofi S.A.
•    DermBiont, Inc.
•    EnteroBiotix Ltd
•    YSOPIA Bioscience
•    Winclove Probiotics
•    TargEDys
•    Evelo Biosciences, Inc.
•    BiomX
•    Biomica Ltd.
•    Scioto Biosciences, Inc.
•    Lactobio A/S

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report provides an exhaustive list of pipeline products which are currently in the development along with their developmental details in various indications. This can help organizations in understanding the research activities, which is the promising indication to pursue or which organization has the potential product to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit.

Growth/Marketing Strategy: In addition to pursuing research on exploring the benefits of microbiome therapeutics for new indications, companies are evaluating next-generation-probiotics (NGPs) to address clinical conditions. Looking at the storage issues of microbiome therapeutics, companies are exploring extracellular vesicles as an alternative option. Furthermore, companies are working on increasing consumer awareness about Microbiome therapeutics and its potential benefits of being natural product containing live microorganism derived from human body as well as pursuing synergistic activities to bring an effective microbiome therapeutics for the affected population.

Competitive Strategy: Key players in the global microbiome therapeutics market were analyzed and profiled in the study, who are developing products containing live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT) as well as next-generation-probiotics (NGPs). Moreover, a detailed competitive benchmarking of the players operating in the global microbiome therapeutics market has been done to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Get Free Sample Report -https://bisresearch.com/requestsample?id=1326type=download

BIS Related Studies

Cancer Microbiome Sequencing Market - A Global and Regional Analysis

Global Skin Microbiome Modulators Market

Global Human Microbiome Modulators Market – Analysis and Forecast, 2018-2023

Article source: https://article-realm.com/article/Business/33246-Microbiome-Therapeutics-Market-Foreseen-to-Grow-Exponentially-by-2032.html